110 related articles for article (PubMed ID: 38011535)
1. Exploiting the "Hot-Spots" of Hsp70
Wang Z; Zhang H; Li X; Song Y; Wang Y; Hu Z; Gao Q; Jiang M; Yin F; Yuan L; Liu J; Song T; Lu S; Xu G; Zhang Z
J Med Chem; 2023 Dec; 66(23):16377-16387. PubMed ID: 38011535
[TBL] [Abstract][Full Text] [Related]
2. Small-molecule inhibitor targeting the Hsp70-Bim protein-protein interaction in CML cells overcomes BCR-ABL-independent TKI resistance.
Song T; Guo Y; Xue Z; Guo Z; Wang Z; Lin D; Zhang H; Pan H; Zhang X; Yin F; Wang H; Uwituze LB; Zhang Z
Leukemia; 2021 Oct; 35(10):2862-2874. PubMed ID: 34007045
[TBL] [Abstract][Full Text] [Related]
3. Bcr-Abl drives the formation of Hsp70/Bim PPI to stabilize oncogenic clients and prevent cells from undergoing apoptosis.
Zhang H; Song T; Wang Z; Laura Bonnette U; Guo Y; Wang H; Gao Q; Zhang Z
Biochem Pharmacol; 2022 Apr; 198():114964. PubMed ID: 35182521
[TBL] [Abstract][Full Text] [Related]
4. Exploring the binding mechanism of a small molecular Hsp70-Bim PPI inhibitor through molecular dynamic simulation.
Li X; Wang Y; Jiang M; Yin F; Zhang H; Yuan L; Liu J; Wang X; Wang Z; Zhang Z
J Mol Model; 2024 Feb; 30(3):71. PubMed ID: 38351232
[TBL] [Abstract][Full Text] [Related]
5. A novel Hsp70 inhibitor specifically targeting the cancer-related Hsp70-Bim protein-protein interaction.
Wang Z; Song T; Guo Z; Uwituze LB; Guo Y; Zhang H; Wang H; Zhang X; Pan H; Ji T; Yin F; Zhou S; Dai J; Zhang Z
Eur J Med Chem; 2021 Aug; 220():113452. PubMed ID: 33906046
[TBL] [Abstract][Full Text] [Related]
6. Small molecule inhibitor targeting the Hsp70-Bim protein-protein interaction in estrogen receptor-positive breast cancer overcomes tamoxifen resistance.
Song T; Zhang H; Zhao Q; Hu Z; Wang Z; Song Y; Zhang Z
Breast Cancer Res; 2024 Feb; 26(1):33. PubMed ID: 38409088
[TBL] [Abstract][Full Text] [Related]
7. Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds.
Aichberger KJ; Mayerhofer M; Krauth MT; Vales A; Kondo R; Derdak S; Pickl WF; Selzer E; Deininger M; Druker BJ; Sillaber C; Esterbauer H; Valent P
Cancer Res; 2005 Oct; 65(20):9436-44. PubMed ID: 16230407
[TBL] [Abstract][Full Text] [Related]
8. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M
Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012
[TBL] [Abstract][Full Text] [Related]
9. Hsp70-Bim interaction facilitates mitophagy by recruiting parkin and TOMM20 into a complex.
Song T; Yin F; Wang Z; Zhang H; Liu P; Guo Y; Tang Y; Zhang Z
Cell Mol Biol Lett; 2023 May; 28(1):46. PubMed ID: 37237369
[TBL] [Abstract][Full Text] [Related]
10. Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant.
Jin B; Wang C; Shen Y; Pan J
Cell Death Dis; 2018 Jan; 9(2):68. PubMed ID: 29358661
[TBL] [Abstract][Full Text] [Related]
11. Bim transfer between Bcl-2-like protein and Hsp70 underlines Bcl-2/Hsp70 crosstalk to regulate apoptosis.
Zhang H; Guo Z; Guo Y; Wang Z; Tang Y; Song T; Zhang Z
Biochem Pharmacol; 2021 Aug; 190():114660. PubMed ID: 34153292
[TBL] [Abstract][Full Text] [Related]
12. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).
Lu T; Cao J; Zou F; Li X; Wang A; Wang W; Liang H; Liu Q; Hu C; Chen C; Hu Z; Wang W; Li L; Ge J; Shen Y; Ren T; Liu J; Xia R; Liu Q
Eur J Pharmacol; 2021 Apr; 897():173944. PubMed ID: 33581133
[TBL] [Abstract][Full Text] [Related]
14. Identification by molecular dynamic simulation and in vitro validation of SISB-A1, N-[1-(4-bromophenyl)-3-methyl-1H-pyrazol-5-yl]-2-[(2-oxo-4-phenyl-2H-chromen-7-yl) oxy], as an inhibitor of the Abl
Al Shahrani M; Gahtani RM; Abohassan M; Alasmari S; Makkawi M
Med Oncol; 2023 Oct; 40(11):316. PubMed ID: 37789230
[TBL] [Abstract][Full Text] [Related]
15. Blockade of the interaction between Bcr-Abl and PTB1B by small molecule SBF-1 to overcome imatinib-resistance of chronic myeloid leukemia cells.
Elgehama A; Chen W; Pang J; Mi S; Li J; Guo W; Wang X; Gao J; Yu B; Shen Y; Xu Q
Cancer Lett; 2016 Mar; 372(1):82-8. PubMed ID: 26721204
[TBL] [Abstract][Full Text] [Related]
16. The HDAC6 inhibitor 7b induces BCR-ABL ubiquitination and downregulation and synergizes with imatinib to trigger apoptosis in chronic myeloid leukemia.
Losson H; Gajulapalli SR; Lernoux M; Lee JY; Mazumder A; Gérard D; Seidel C; Hahn H; Christov C; Dicato M; Kirsch G; Han BW; Schnekenburger M; Diederich M
Pharmacol Res; 2020 Oct; 160():105058. PubMed ID: 32619722
[TBL] [Abstract][Full Text] [Related]
17. GILZ inhibits the mTORC2/AKT pathway in BCR-ABL(+) cells.
Joha S; Nugues AL; Hétuin D; Berthon C; Dezitter X; Dauphin V; Mahon FX; Roche-Lestienne C; Preudhomme C; Quesnel B; Idziorek T
Oncogene; 2012 Mar; 31(11):1419-30. PubMed ID: 21804606
[TBL] [Abstract][Full Text] [Related]
18. Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells.
Matsuda Y; Yamauchi T; Hosono N; Uzui K; Negoro E; Morinaga K; Nishi R; Yoshida A; Kimura S; Maekawa T; Ueda T
Cancer Sci; 2016 Jul; 107(7):1029-38. PubMed ID: 27166836
[TBL] [Abstract][Full Text] [Related]
19. MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells.
Yeh YY; Liou JP; Lee YL; Lin JY; Huang HM
Invest New Drugs; 2017 Aug; 35(4):427-435. PubMed ID: 28349229
[TBL] [Abstract][Full Text] [Related]
20. Hsp70-Bim incoherent feedforward loop contributes to cell-fate heterogeneity and fractional killing.
Yin F; Song T; Wang Z; Liu J; Zhang H; Tang Y; Zhang Z
Br J Pharmacol; 2024 Mar; 181(5):659-669. PubMed ID: 37706555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
